BST2 and cancer: Although a specific subset of ISGs (including IFI27, ISG15, BST2, OAS1, OAS3, and OASL) that comprise an IFN-related DNA damage–resistant signature (IRDS) are upregulated in cancer cells and induce an unfavorable response to anticancer immunity (55–57), their functions are not associated with cancer metabolism.